KALA BIO has transitioned into a high-risk, pre-revenue clinical-stage entity, with its future entirely contingent on the success of the KPI-012 MSC-S platform.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 19, 2026 | -$21.32-255.3% vs -$6.00 | — vs — |
Q2 2026 May 15, 2026 | -$0.14+98.4% vs -$8.50 | — vs — |
Q2 2026 Apr 15, 2026 | $0.08+100.5% vs -$16.00 | — vs — |
Q4 2025 Nov 19, 2025 | -$1.07+97.9% vs -$50.50 | — vs — |
KALA BIO, Inc. (NASDAQ: KALA - Get Free Report) was the target of a large growth in short interest in September. As of September 30th, there was short interest totaling 1,358,824 shares, a growth of 205.1% from the September 15th total of 445,421 shares. Approximately 7.2% of the company's stock are short sold. Based on an
KALA BIO, Inc. (NASDAQ: KALA - Get Free Report) shares fell 0.9% during mid-day trading on Friday. The stock traded as low as $0.2860 and last traded at $0.2940. Approximately 285,090 shares traded hands during trading, a decline of 92% from the average daily volume of 3,782,051 shares. The stock had previously closed at $0.2966. Wall
Proposed Acquisition Valued at Approximately $15 Million Would Add an Established 50-State Telehealth Business, with over 90,000 clients, Focused on Peptides such as GLP-1 Weight Management, Hormone Health, Longevity and Sexual Wellness Key Highlights Target generated approximately $12.7 million in revenue for the trailing twelve months ended August 2026 (unaudited, as provided by Target management) and is cash-flow positive Proposed purchase price of approximately $15 million, payable in cash and KALA stock; the cash portion is expected to be funded from existing balance sheet resources Founded in 2023; LegitScript-certified, NABP-accredited platform serving clients in all 50 states; more than 90,000 clients served since inception 45-day due diligence period expected to conclude in November 2026; definitive agreements and closing targeted for late 2026 or early 2027 New York, New York--(Newsfile Corp. - September 29, 2026) - KALA Bio, Inc. (NASDAQ: KALA) ("KALA" or the "Company") today announced that on September 24, 2026, it signed a non-binding letter of intent ("LOI") for the proposed acquisition of 100% of a privately held, U.S.-based management services organization ("MSO") supporting a LegitScript-certified, NABP-accredited provider-led telehealth platform serving clients in all 50 states (the "Target"). Based on unaudited financial information provided by the Target's management, the Target generated approximately $12.7 million in revenue for the trailing twelve months ended August 2026.
Agreement would expand the companies' genetic testing collaboration beyond ophthalmology to a selected suite of genomic testing products through an additional U.S. reseller channel Agreement would expand the companies' genetic testing collaboration beyond ophthalmology to a selected suite of genomic testing products through an additional U.S. reseller channel
Benchmark KALA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for KALA BIO, Inc. (KALA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.16 | $11.56K | -0.00 | — | — | -222.32% | — | |
| $6.60 | $1.45B | -4.93 | -18.67% | -579.1% | -59.87% | — | |
| $100.61 | $6.55B | 25.50 | 0.5% | 17.28% | 21.72% | — | |
| $26.89 | $1B | -26.98 | 36.41% | -13.51% | -104.9% | — | |
| $10.08 | $548.45M | -19.57 | -3.13% | -32.13% | -51.66% | — | |
| $13.28 | $1.54B | -12.74 | 8.28% | -16.78% | -35.81% | — |
KALA BIO, Inc. (KALA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
KALA BIO, Inc. (KALA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 23, 2026·SEC
May 7, 2026·SEC
Mar 4, 2026·SEC
Get notified when KALA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
KALA BIO, Inc. (KALA) stock FAQ — growth, dividends, profitability & financials explained
No. KALA BIO, Inc. (KALA) reported a net loss of $10.1M over the trailing twelve months.
KALA BIO, Inc. (KALA) had a return on equity (ROE) of -222.3% over the trailing twelve months. A negative ROE means the company lost money over the period.
KALA BIO, Inc. (KALA) had negative free cash flow of $19.9M over the trailing twelve months.
